Combined Covid vaccine and flu, first positive data

Biotech firm

has announced the positive results of the Phase 1/2

of its

.

The data, presented at the

, demonstrated the ability of the Cic vaccine to generate immune responses against the SarsCoV2 virus and homologous and heterologous influenza strains.

Cic combines Novavax's Covid19 vaccine and the potential quadrivalent influenza vaccine in a single formulation. 

The combined vaccine formulations, the company explains in a note, generated strong antibody responses against both SarsCoV2 and influenza antigens.

The confirmatory dose study (phase 2) will begin by the end of 2022. "Today's results demonstrate that our Covid-influenza combination vaccine candidate is not only feasible, but is also well tolerated and capable of inducing both antibody responses. that of T cells - says Gregory M. Glenn, president of the research and development division of Novavax -. We are experiencing a period of transition towards an endemic circulation of the virus. We believe that our combined protein-based vaccine can help address 'single formulation two threats to global public health ".